Breaks Categories: News

TuesdayMay 30, 2023 12:39 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Enters SAA with Samsung

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced its entry into a strategic alliance agreement (“SAA”) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired LIVMOR assets earlier this year. Under the agreement, HeartBeam and Samsung will identify and define opportunities for collaboration, tapping the HeartBeam team’s expertise and patented technology in the assessment and monitoring of cardiac symptoms. “The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing…

Continue Reading

ThursdayMay 25, 2023 2:42 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the appointment of Dr. Eric Hoskins to its board of directors. A medical doctor, Dr. Hoskins is specialized in public health and presently a partner at Maverix Private Equity in Toronto. From 2014 to 2018, he was Ontario’s Minister of Health and Long-Term Care. His esteemed career spans nearly four decades, where Dr. Hoskins has built a reputation of expertise in public health,…

Continue Reading

ThursdayMay 25, 2023 2:23 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Granted Key Patent for Use in Innovative System Designed to Help Evaluate Cardiac Symptoms

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office informing the company of the key patent, which relates to the initial AI capability in the form of an expert system for the AIMIGo System. The patent, titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment,” outlines a system that combines the recorded cardiac…

Continue Reading

ThursdayMay 25, 2023 2:13 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, has enrolled 134 patients. This represents more than 50% of the total planned enrollment for the study. “The achievement of this milestone in any study is no small feat. The dedication of our team and the proficiency of their operational execution continues to be…

Continue Reading

ThursdayMay 25, 2023 12:54 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at two upcoming investor events. The company announced that members of its executive team will be participating in the Tribe Public Webinar, slated for May 31, 2023, and the Investor Summit, scheduled for June 1, 2023. According to the announcement, InMed CEO Eric A. Adams and BayMedica VP of sales and marketing Jerry Griffin will cohost a presentation for the Tribe Public Webinar. The virtual presentation, titled “Addressing the Increasing Demand for Rare Cannabinoids,” will begin at…

Continue Reading

MondayMay 22, 2023 11:17 am

BioMedNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Releases Details of Common Share Offering

Universal Ibogaine (TSX.V: IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, has announced an offering of up to 66,666,667 shares. The shares will be offered $0.03 per share, which could result in approximately $2 million in gross proceeds. According to the announcement, each unit will include one common share and a one-half common share purchase warrant, with each whole warrant giving the holder the right to purchase an additional UI common share at $0.06 per share; that right will be available for up to one year after the offering closes. UI anticipates using the offering…

Continue Reading

FridayMay 19, 2023 12:37 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at an upcoming Water Tower Research Fireside Chat Series. The company announced that CEO Eric A. Adams will be the featured speaker at the May 23, 2023, fireside chat; the event is slated to begin at 1 p.m. ET. During the chat, Adams will present an overview of the company’s pharmaceutical development pipeline. He will also discuss subsidiary BayMedica and its anticipated impact on InMed's growth as well as upcoming catalysts for the company. A replay of the…

Continue Reading

ThursdayMay 18, 2023 1:26 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its HeartBeam AIMIGo(TM) System. The HeartBeam AIMIGo System is a personal, portable and easy-to-use VECG solution to assist patients and their clinicians in assessing cardiac symptoms. The breakthrough solution employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data in real-time outside of a medical setting. “The 510(k) submission of our HeartBeam AIMIGo…

Continue Reading

TuesdayMay 16, 2023 1:23 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company has been awarded approximately C$2.81 million in an arbitration settlement. An InvestmentPitch Media video provides additional information about this news and the company. The video is available for viewing on InvestmentPitch and YouTube. To view the full press release, visit https://ibn.fm/2G1zT About FSD Pharma Inc. FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, a wholly owned…

Continue Reading

TuesdayMay 16, 2023 12:58 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting its financial results for the first quarter ended March 31, 2023; the report also noted key business updates. Highlights of the report indicate R&D expenses for quarter totaled $2 million with marketing, general and administrative expenses for the quarter reaching $1.2 million and total operating expenses coming in at $3.2 million, compared with $2.6 for same period in 2022. The report noted financial (loss) income for the quarter totaling $(0.3) million compared with $0.14 million for…

Continue Reading